Blogs
Modern eCOA/ePRO: A people-first approach paves the way for better data collection
Chief Patient Officer and Co-founder, Bruce Hellman, discusses how modern eCOA/ePRO systems can pave the way for better, human-centric data collection.
SCDM 2023 – patient-centricity in clinical data management
In our latest blog, uMotif’s Chief Patient Officer and Co-founder, Bruce Hellman discusses his takeaways from his recent trip to San Diego for the 2023 Society of Clinical Data Managers (SDCM) 25th anniversary conference.
Pfizer’s initiative to return clinical trial data to patients recognizes participant contributions and sets the pace for the industry
uMotif’s Cheif Patient Officer/ Co-founder, Bruce Hellman celebrates Pfizer’s decision to return individual clinical trial data to patients at scale – in an easy-to-understand format – and explores the impact of expanding data return to real time, when feasible.
What does it take to be a modern eCOA/ePRO platform?
uMotif’s Chief Product Officer, Julia Lakeland shares her knowledge on the qualities that define and distinguish modern eCOA/ePRO, and why they matter to sponsors, CROs, clinical trial sites, and most importantly patients.
Three questions with Ben James
As we continue our ‘Three Questions with’ series, uMotif’s Chief Design Officer and Co-founder provides insight into the importance of prioritizing human-centricity in the design of modern eCOA/ePRO platforms and shares his thoughts on the future growth of eCOA/ePRO.
OurBrainBank (OBB) to improve the quality of life for glioblastoma patients
Glioblastoma Multiforme (GBM) is the most invasive and lethal type of brain cancer. uMotif is honored to have known and collaborated with the Glioblastoma charity, Our Brain Bank and Founder, Jessica Morris – in her quest to improve and extend the lives of those with GBM.
Three questions with Bruce Hellman
uMotif’s Chief Patient Officer and Co-founder shares our vision for giving patients the best experience possible and provides insights into how sponsors and CROs can transform study protocols and the participant experience with ePRO/eCOA.
100 for Parkinson’s study
This study was designed to help participants learn more about their own health, better understand how technology can support people living with Parkinson’s, and build a research dataset to drive new insights.
Three questions with Kristine Klinger
Chief Delivery Officer Kristine Klinger discusses her vision for uMotif’s service delivery and our culture of continuous improvement. Kristine also provides some practical advice for companies interested in incorporating eCOA/ePRO technology.
Guidance on Use of Patient Experience Data in Real World studies – EU Perspectives
Patient insights are expected to become increasingly instrumental in optimising medicine development and regulatory decision making.
uMotif eCOA/ePRO Platform Helps to Expand Understanding of Hypoglycaemic Events
Patient engagement expert and uMotif sales leader Peter Robinson shares insight at the 2023 International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) – Feb. 22-25, Berlin.
Three questions with Julia Lakeland
In the latest in our ‘Three questions with’ series, Chief Product Officer, Julia Lakeland discusses current trends in the eCOA/ePRO industry and how sponsors and regulators can improve patient engagement.
CNS Summit 2022 Boca was buzzing with patient-centricity
Our Chief Patient Office Bruce Hellman attended the CNS Summit held in Boca Raton, Florida and discovered that true patient centricity is the way forward for patient trials.
ISPOR 2022 – The continued rise of the Patient Reported Outcome
Bruce Hellman Chief Patient Officer reflects on his key learnings from this year’s ISPOR assembly on the future of the life sciences industry.
Digital Era Expands Scope and Impact for Medical Affairs. Prepare to Rise to the Challenge
With the rise of digital technology expanding the role of Medical Affairs, our Chief Product Officer, Julia Lakeland explains how Medical Affairs has a critical role to play in serving as the bridge between patients and pharmaceutical companies to ensure patient safety and improve outcomes.
Three things I learned at the PCMG 2022 assembly – “ The ‘I’ of the Storm”
Bruce Hellman reflects on his time at this year’s ISPOR—The Professional Society for Health Economics and Outcomes Research conference.